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ABSTRACT
Background. Antidiabetic agents such as glucagon-like 
peptide-1 receptor agonists (GLP-1RAs) and sodium 
glucose cotransporter-2 inhibitors (SGLT2i) are known 
to improve glycaemic control with favourable impact 
on cardiovascular (CV) risk factors. Given the potential 
benefits, this study evaluated the clinical effectiveness 
of combination therapy including dulaglutide, SGLT2i 
and metformin with or without insulin in Indian adults 
with inadequately controlled T2DM. 
Material and methods. This retrospective, real-world, 
single-centre study included 15 adults (mean age 
[SD, standard deviation]: 49.47 [9.29] years) with 
inadequately controlled T2DM. The patients received 
a combination of dulaglutide, SGLT2i and metformin 
with or without insulin. Changes in fasting blood 
glucose (FBG), postprandial blood glucose (PPBG), 
glycosylated haemoglobin (HbA1c), body weight, 
BMI, vascular age (VA), systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) were examined for 
a follow-up duration of 3 months. Self-reported ad-
verse events were also recorded. 
Results. At the 3-month follow-up, the combination 
therapy resulted in significant reduction (P < 0.001) in 
glycaemic parameters such as FBG, PPBG and HbA1c with 
a mean reduction (MR [SD]) of 66.67 (40.05) mg/dL, 83.33 
(64.11) mg/dL and 1.78 (1.08) % respectively. A significant 
reduction (P < 0.001) in body weight and corresponding 
BMI was demonstrated with an MR (SD) of 6.40 (3.96) kg 
and 2.67 (1.63) kg/m2 respectively. Similarly, significant 
reductions (P < 0.05) were also recorded for SBP (4.40 
[4.61] mm Hg) and DBP (2.80 [3.84] mm Hg). The therapy 
was also associated with significant reduction (P < 0.001) 
in VA (MR [SD]: 3.93 [2.46] years). The therapy was well 
tolerated; however, self-reported gastrointestinal symp-
toms were reported in 5 patients, which subsided within 
2 weeks of therapy initiation. 
Conclusion. Combination therapy with dulaglutide, 
SGLT2i and metformin with or without insulin resulted 
in significant improvements in glycaemic parameters, 
body weight and SBP in Indian adults with inad-
equately controlled T2DM. Interestingly, there was 
a significant improvement in vascular age associated 
with the therapy. (Clin Diabetol 2020; 9)
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Introduction 
Type 2 diabetes mellitus (T2DM) is considered 
a global epidemic affecting nearly 90% of population 
world-wide. Patients with T2DM are usually presented 
with comorbidities including hypertension, hyperlipi-
daemia, obesity and are therefore prone to cardiovascu-
lar (CV) risk [1]. Management of T2DM is complex given 
the progressive nature of the disease and associated 
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co-morbidities. As the disease progresses, clinicians 
involved in diabetes care often tackle with the challenge 
of adjusting multiple medications in the face of renal 
failure and CV disease. In addition, medications have 
to be tailored to help patients overcome intolerances 
and adverse effects [2]. 
Newer generation glucose-lowering drugs, gluca-
gon-like peptide-1 receptor agonists (GLP-1RA) and 
sodium glucose cotransporter-2 inhibitors (SGLT2i) 
have made a remarkable breakthrough into the T2DM 
treatment armamentarium enabling a patient centred 
approach. The complimentary mechanisms of action 
demonstrated by GLP-1RA and SGLT2i with respect 
to cardio and nephroprotective effects are generat-
ing their potential need and are currently attracting 
significant attention from medical research communi-
ties [3]. Cardiovascular outcome trials (CVOT) have 
demonstrated significant reductions in major adverse 
cardiovascular events (MACE) and mortality outcomes 
with GLP-1RA (LEADER, EXCEL, SUSTAIN-6) and SGLT2i 
(EMPA-REG, CANVAS) [4]. To further support this 
evidence, REWIND, the first CVOT trial for dulaglutide 
that included a majority of participants who did not 
have an established cardiovascular disease, is reported 
to have demonstrated superiority in the reduction of 
MACE [5]. Based on evidence from pivotal trials (DU-
RATION-8, AWARD-10) and other recently published 
real-world observational studies, patients with poorly 
controlled T2DM treated with GLP-1RA as an add-on 
to SGLT2i have shown beneficial effects on glycaemic 
control, body weight and SBP with low hypoglycaemia 
risk compared with those assigned to placebo [1, 4, 
6, 7]. A literature review on the efficacy of combined 
treatment with GLP-1RA and SGLT2i showed additive 
effect on lowering the HbAlc levels, systolic blood pres-
sure (SBP), diastolic blood pressure (DBP) and body 
weight in patients with T2DM. The combination therapy 
may therefore address multiple facets of the disease 
and may prove to be a potential additive in lowering 
cardiorenal risk in addition to glycaemic control [1, 8]. 
The aim of this retrospective, real-world, single-
centre study is to evaluate the impact of combination 
therapy with once-weekly dulaglutide, SGLT2i and met-
formin with or without insulin on fasting blood glucose 
(FBG), post prandial blood glucose (PPBG), HbA1c, body 
weight, body mass index (BMI), vascular age (VA), SBP 
and DBP in Indian patients with inadequately controlled 
T2DM in a real-world setting.
Materials and methods
Study design and participants
This retrospective, real-world, single-centre obser-
vational study was carried out at the AMRI Hospital, 
a tertiary care centre in Salt Lake, Kolkata, India between 
January, 2018 to March, 2018. Eligible patients (N = 15) 
were adults (mean age, 49.47 ± 9.29 years) with 
inadequately controlled T2DM. The mean duration of 
diabetes was 7.6 ± 1.24 years. All participants were 
receiving antidiabetic medications which included 
a full dose of gliptin (Sitagliptin [100 mg] or Vildaglip-
tin [100 mg] or Linagliptin [5 mg]) and a full dose of 
Glimepiride (4 mg). Patients were stopped on these 
medications and shifted to a combination therapy with 
once-weekly dulaglutide (1.5 mg or 0.75 mg up-titrated 
to 1.5 mg), SGLT2i (canagliflozin [100 mg or 300 mg], 
empagliflozin [25 mg] or dapagliflozin [10 mg]) and 
metformin (500 mg or 1000 mg). Insulin glargine or 
degludec were subsequently required in 4 out of 15 
patients to achieve a target FBS of 90–110 mg. The aver-
age dose of Basal Insulin was 8.35 ± 0.45 IU. Patients 
with type 1 diabetes, history of pancreatitis, family 
history of medullary thyroid cancer, or multiple endo-
crine neoplasia type 2 were excluded from this study. 
All patients were on statins and antihypertensives (to 
achieve individualised optimal target SBP and DBP) in 
addition to antidiabetic medications. Mean SBP 122.87 
± 4.81 mm Hg and mean DBP 84.27 ± 4.95 mm Hg.
Data analysis was conducted for patients, who 
were able to complete three months of therapy. 
Endpoint assessment
Changes in clinical parameters including, FBG, PPBG, 
HbA1c, body weight, BMI, VA, SBP and DBP were assessed 
at baseline and 3 months after treatment. AGEDIO B900 
Pulse Wave Analysis System (Hibernia Medical). This in-
strument has a BP cuff that can be attached to the arms, 
a recording machine and a software which generates 
reports on the vascular age, based on the age, body 
weight, SBP and DBP and the arterial stiffness.
The report is generated in reference to the chrono-
logical age of the individual, i.e. same as or number 
of years more than or less than the chronological age.
Agedio is a screening service for arterial stiffness 
called VA measurement for the pharmacy store or other 
health care centers. The technology offers an (upper-
arm) cuff-based blood pressure and arterial stiffness 
measurement within one single procedure. Arterial 
stiffness is quantified with the aortic pulse wave velocity 
(PWV), measured in m/s. Agedio consists of a validated 
measurement device and the displaying device, an iPad. 
It allows for a measurement within a few minutes and 
provides two detailed reports one for the patient and 
one for the physician. The medical report in addition 
to arterial stiffness includes the hemodynamic figures 
such as cardiac output, total vascular resistance and 
central (aortic) blood pressure.
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Clinical indications for technology are as follows: 
Cardiovascular diseases such as coronary heart dis-
ease globally are the leading cause for morbidity and 
mortality. Risk assessment via blood pressure, LDL 
measurement or by using traditional risk scores such as 
Framingham and SCORE have shown to be insufficient 
for detecting the individual risk of a patient. The pro-
portion of patients receiving inadequate treatment for 
cardiovascular diseases, such as high blood pressure, 
is alarmingly high. Existing measurement methods for 
blood pressure measurement do not provide enough 
medical information about the pathophysiological 
individual background of the patients.
Therefore, Agedio improves the current situation 
by following indications:
 — leverage of patient awareness by using informative 
and catchy patient reports (pharmacy), supports 
the encouragement of patient therapy adherence;
 — precise identification and classification of patients 
into low, medium and high risk patients (medical 
doctor);
 — provision of hemodynamic figures for support in 
therapeutic decisions and thereby related clinical 
benefits, such as reduction of cardio-vascular events 
as strokes and myocardial infarctions (discovery). 
The hemodynamic figures provide for a solid 
foundation of therapeutic decisions and benefits. 
They may provide the rationale for improved applica-
tion for existing anti-hypertensive and other drugs. 
In comparison to regular therapy decision making, 
this advanced measure reduces emergency visits and 
re-hospitalization related to new cardiovascular and 
coronary events by 40%.
The added value of risk prediction of PWV, above 
and beyond traditional risk factors, including SCORE 
and Framingham, has been quantified in a number 
of studies. The net classification value (NRI, net re-
classification index) of PWV measurement allows for 
both, patient re-classification into higher or lower 
risk categories. The results have a direct influence on 
therapeutic decisions.
Agedio is a main point of action for stakeholders 
involved in public health, focusing on services within 
the pharmacy. Do you know your vascular age is a 
concept intended for a long-term partnership between 
pharmacists, medical professionals, health insurance 
companies and patients.
Adverse events following therapy administration 
were also recorded.
Statistical methods
All statistical analysis was performed using R 3.4.1 
and MS-Excel software. Comparison between baseline 
and follow-up value of various parameters was done 
using paired t test. Continuous variables were pre-
sented as mean (standard deviation [SD]) with 95% 
CI as applicable and categorical data were presented 
as proportions. All P values were 2-sided and were 
considered significant if P < 0.05.
Results
Baseline demographics
A total of 15 (male: 9 and female: 6) patients 
received combination therapy with once-weekly dula-
glutide, SGLT2i and metformin with or without insulin 
for 3 months. Baseline characteristics of the study 
population are presented in Table 1. 
Impact on clinical outcomes 
Improvement in clinical outcomes with dulaglutide 
as add-on therapy is presented in Table 2.
Glycaemic parameters
A significant decline (P < 0.001) in FBG, PPBG and 
HBA1c from baseline with a mean reduction (MR) of 
66.67 mg/dL, 83.33 mg/dL and 1.78% respectively was 
demonstrated at 3-months follow-up.
Non-glycaemic parameters
Body weight
The therapy demonstrated a significant reduction 
(P < 0.001) in body weight (MR: 6.40 kg) and corre-
sponding BMI (MR: 2.67 kg/m2) at 3-month follow-up.
Vascular age
The therapy was associated with a significant reduc-
tion (P < 0.001) in VA (MR: 3.93 years) at the follow-up.
Table 1. Baseline demographics of the study group
Variable Baseline 
Mean (SD)
Age (years) 49.47 (9.29)
FBG [mg/dL] 201.67 (62.13)
PPBG [mg/dL] 248.20 (5.67)
HbA1c (%) 8.61 ± 1.41
Body weight [kg] 98.60 ± 14.05
BMI [kg/m2] 32.27 ± 4.67
VA (years) 53.73 ± 7.62
SBP [mm Hg] 129.87 ± 4.81
DBP [mm Hg] 84.27 ± 4.95
BMI — body mass index; CI — confidence interval; DBP — diastolic blood 
pressure; FBG — fasting blood glucose; HbA1c — glycosylated haemoglo-
bin; LCL — lower confidence limit; PPBG — postprandial blood glucose; 
SBP — systolic blood pressure; SD — standard deviation; UCL — upper 
confidence limit; VA — vascular age
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Blood pressure
Follow-up at 3-months demonstrated a significant 
reduction (P < 0.05) in SBP (MR: 4.40 mm Hg and DBP 
(MR: 2.80 mm Hg).
Adverse events
Self-reported gastrointestinal symptoms were ob-
served in 5 (33.33%) patients which included nausea 
and bloated abdomen. All adverse events subsided 
within 2 weeks of therapy initiation. Pantoprazole and 
domperidone combination were administered in 3 out 
of the 5 patients to mitigate the gastrointestinal side ef-
fects. No cases of severe hypoglycaemia were reported.
Discussion
Patients with T2DM often present metabolic and 
cardio-renal co-morbidities, adding complexity to dia-
betes care. With the advent of newer drugs such as GLP-
-1RA and SGLT2i, the diabetes treatment is undergoing 
a paradigm shift towards improved diabetes care [7]. 
The current study evaluated the clinical effectiveness 
of combination therapy with once-weekly dulaglutide, 
SGLT2i and metformin with or without insulin in Indian 
adults with T2DM. 
This study demonstrated significant reductions in 
glycaemic parameters such as FBG, PPBG, HbA1c for a 
follow-up period of 3 months. In addition, a significant 
reduction in body weight and BMI was observed. This 
is supported by one of the pivotal clinical trials for 
dulaglutide, AWARD-10 which compared the efficacy 
of combination therapy of dulaglutide and SGLT2i 
versus placebo and SGLT2i in patients with T2DM. 
Patients who received dulaglutide as an add-on to 
SGLT2i showed statistically superior improvements in 
glycaemic control compared with placebo and SGLT2i. 
Similarly changes in weight, FBG and SBP was greater 
for the dulaglutide arms compared with placebo [9]. 
This finding is also in-line with another real-world 
study wherein the effectiveness of co-administration 
of GLP-1RA and SGLT2i was evaluated [7]. Notably, 
in a retrospective observational study by Curtis et al., 
which assessed the effect of combination of add-on 
therapy of GLP-1RA and SGLT2i on glycaemic control 
and weight in T2DM patients, reported significantly 
larger reduction in HbA1c with dual therapy (GLP-1RA 
and an SGLT2i) compared with a diabetic regimen with 
GLP-1RA alone. This effect was sustained along with 
the additional benefit of further weight loss in 58% 
of the patients on dual add-on therapy compared to 
single GLP-1 therapy [10]. 
Clinically relevant improvement in daily and long-
term glucose control with combined use of dulaglutide 
and SGLT2 inhibitors is important in the context of the 
differences in mechanisms of actions between GLP-1 
receptor agonists and SGLT2 inhibitors — enhance-
ment of insulin secretion and glucagon suppression 
with GLP-1 receptor agonists versus increased urinary 
glucose excretion and glucagon stimulation with SGLT2 
inhibitors. Understanding the effect on glucagon was 
of special interest in this study because treatment 
with SGLT2 inhibitors has been shown to increase 
glucagon concentrations, potentially interfering with 
glucagon-lowering actions of GLP-1 receptor agonists. 
Importantly, both dulaglutide doses suppressed serum 
glucagon secretion, with dulaglutide 1∙5 mg achieving 
a significantly greater reduction from baseline versus 
placebo, consistent with the reductions in fasting 
glucagon concentration of similar magnitude reported 
in other studies of dulaglutide. The preserved effect of 
dulaglutide on glucagon when added to SGLT2 inhibi-
Table 2. Improvement in outcomes from baseline to follow-up in the overall population
Variable Mean improvement Standard deviation 95%CI (LCL, UCL) P value
Glycaemic parameters
FBG [mg/dL] 66.67 40.05 (46.40–86.93) < 0.001
PPBG [mg/dL] 83.33 64.11 (50.89–115.78) < 0.001
HbA1c (%) 1.78 1.08 (1.24–2.33) < 0.001
Non-glycaemic parameters
Body weight [kg] 6.40 3.96 (4.40–8.40) < 0.001
BMI [kg/m2] 2.67 1.63 (1.84–3.49) < 0.001
VA (years) 3.93 2.46 (2.69–5.18) < 0.001
SBP [mm Hg] 4.40 4.61 (2.07–6.73) < 0.05
DBP [mm Hg] 2.80 3.84 (0.86–4.74) < 0.05
BMI — body mass index; CI — confidence interval; DBP — diastolic blood pressure; FBG — fasting blood glucose; HbA1c — glycosylated haemoglobin;  
LCL — lower confidence limit; PPBG — postprandial blood glucose; SBP — systolic blood pressure; SD — standard deviation; UCL — upper confidence limit; 
VA — vascular age
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tor treatment might be an important contributor to 
the overall glucose-lowering potency in this patient 
This preserved effect is not seen with dipeptidyl pepti-
dase-4 (DPP-4) inhibitors or liraglutide when added to 
treatment with SGLT2 inhibitors since mean glucagon 
concentrations remained unchanged. This finding is 
potentially due to the lower potency of DPP-4 inhibi-
tors and liraglutide compared with dulaglutide in the 
suppression of glucagon secretion [9]. The reduction 
in HbA1c and bodyweight with dulaglutide 1∙5 mg in 
our study. One possible reason could be related to the 
simulteneous introduction of SGLT2 inhibitor therapy 
in patients on a background of medications which 
were weight neutral. Continuous decrease in HbA1c 
and bodyweight suggest that the bodyweight-lowering 
action of simulteneously introduced SGLT2 inhibitors 
was ongoing during the treatment period.
A significant reduction in SBP and was noted at the 
3-month follow-up. This is in contrast with a real-world 
study by Ghosal et al. which assessed the effectiveness 
of combination therapy with dulaglutide and SGLT2i in 
Indian patients with T2DM. However, the results are in-
line with clinical trial, AWARD-10 as elaborated above 
and other retrospective studies [7, 9]. 
Our study for the first time, reported the changes 
in vascular age as a result of combination therapy with 
dulaglutide and SGLT2i. Vascular age reflects the real 
atherosclerotic damage and is considered as a new 
variable in cardiovascular risk assessment [11, 12]. This 
study demonstrated significant improvement in vascu-
lar age at the follow-up compared with baseline. This 
is important as the assessment of cardiovascular risk is 
a cornerstone in effective prevention and management 
of cardiovascular disease often associated with T2DM. 
Combination therapy was well tolerated; how-
ever, self-reported gastrointestinal symptoms subsided 
within 2 weeks of therapy initiation. There were no 
cases of severe hypoglycaemia reported in this study. 
Study limitations
The most important limitation of this study is lack 
of a comparator arm. This leaves the possibility of risk 
of reporting bias that may affect the results. In addition, 
the study duration was relatively short (3 months). This 
study has a retrospective, single-centre observational 
design and small sample size. In an Indian setting, 
one of the barriers in accessing medications includ-
ing GLP-1RA includes cost which limits the exposure 
of the drug to a narrow pool of patient population. 
Thus, these results might not be reflective of diverse 
patient population adding to selection bias. However, 
the importance of this study was not significantly af-
fected by these limitations.
Conclusion
In a real-world setting, co-administration of dula-
glutide with SGLT2i and other antidiabetic medications 
demonstrated significant improvements in glycaemic 
parameters and SBP. Interestingly, for the first time, the 
study reports improved vascular age with the therapy. 
The therapy was well tolerated with no serious adverse 
events reported. This study therefore provides a pilot 
and indeed generates a hypothesis supporting com-
bination of GLP-1RA, SGLT-2i and other antidiabetic 
drugs, in the management of T2DM, which needs to be 
tested in a more systematic and appropriately powered 
study design. Further research is warranted in terms 
of healthcare resource practice, costs and long-term 
outcomes.
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